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Abstract 
Aims Immunohistochemical assessment of Ki67 expression in core-needle biopsies (CNBs) 
increasingly plays a role in therapeutic decision-making in breast cancer patients. Within the 
framework of same-day diagnostics of breast lesions, fixation times are markedly decreased. 
We therefore attempted to validate Ki67 analysis in briefly fixed breast cancer CNBs. 
Methods and results CNBs of 136 consecutive patients with invasive breast cancer diagnosed 
through the same-day diagnostics programme of both the University Medical Center Utrecht 
(UMCU) and the Radboud University Medical Center (RUMC) were included. CNBs were 
fixed in formaldehyde for approximately 45 minutes in the UMCU and between 60 and 90 
minutes in the RUMC. Immunohistochemistry for Ki67 expression was compared between 
the briefly fixed CNBS and conventionally fixed resection specimens of the same tumor. 
Overall agreement between CNBs and resections was 122/142 (85.9%) for Ki67 expression (κ 
= 0.71; 95% CI = 0.60 – 0.83). Positive and negative predictive values were 79.7% (95% CI = 
0.67 – 0.88%) and 91.0% (95% CI = 0.82 – 0.96%), respectively.  
Conclusions Overall agreement for Ki67 expression was good between briefly fixed CNBs 
and conventionally fixed resection specimens, and within the range of studies comparing 
conventionally fixed CNBs and resections.  
 
Key words: fixation time, Ki67, cell proliferation, immunohistochemistry, core-needle 
biopsy, breast cancer 
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Introduction 
In personalized breast cancer care, various immunohistochemical analyses are nowadays 
applied for therapeutic decision-making. Hereto, markers reflecting proliferation are of great 
interest as they reflect risk of recurrence [1]. One of these markers associated with cell 
proliferation is the nuclear protein Ki67 which has strong prognostic value in breast cancer [2, 
3]. Recently, the International Ki67 in Breast Cancer Working Group stressed the value of 
Ki67 as a predictor of prognosis and as a biomarker for treatment effectiveness [4]. Although 
not yet recommended in national guidelines, Ki67 appears to be widely determined in breast 
cancer tissue during routine clinical practice [5].  
Demand is growing for the standardization of Ki67 assessment because of its important role 
in therapeutic decision-making. Immunohistochemistry has been widely adopted by different 
laboratories as the preferred detection method for Ki67. Nevertheless, preanalytical variables 
may still influence test results. In accordance with guidelines for hormone receptor 
assessment, a minimum fixation time of 6 hours in 10% neutral buffered formalin (NBF; is 
4% neutral buffered formaldehyde) is generally recommended for Ki67 [6]. Within the 
context of increasing demands for same-day diagnostics in breast cancer, speeding up the 
process of tissue handling for biomarker assessment is mandatory. There is already some 
evidence that brief fixation time does not influence Ki67 assessment in other tissue types. 
Munakata et al. studied fixation in NBF for 4 to 48 hours in one tonsil specimen and showed 
that fixation for only 4 hours was adequate for Ki67 analysis [7]. The aim of this double-
centre study was to assess whether even shorter fixation times (45-90 minutes) of same-day 
diagnostic CNBs allows for reliable immunohistochemical assessment of Ki67 expression in 
two cohorts of invasive breast cancer patients. Reporting was done according to the 
REMARK criteria [8]. 
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Materials and methods 
Patients 
Since November 2011 and January 2008, the University Medical Center Utrecht (UMCU) and 
the Radboud University Medical Center (RUMC) [9], respectively, have been operating a 
same-day diagnosis programme for breast lesions. In this programme, patients with suspected 
malignancy are referred for analysis including CNB with the aim of informing patients about 
their diagnosis and suggested treatment regimen within one day. Cohorts of consecutively 
admitted patients with invasive breast cancer (with both CNB and subsequent resection 
performed at the same center) were included from both centres. As we used coded leftover 
material no ethical approval was required based on current Dutch legislation [10, 11]. Patients 
undergoing neo-adjuvant therapy and with multifocal disease (the latter potentially providing 
sampling issues) were excluded from the study, unless correct matching of lesions on CNB 
and the resection could be thoroughly ensured. Mitotic activity index and tumor grade of 
resections was recovered from the databases in both centers to assess inter-laboratory 
differences between the cohorts.  
 
Tissue processing 
In the UMCU, CNBs were immediately placed in NBF and sent to the pathology laboratory to 
be registered (estimated prior fixation time 15 minutes). After registration, specimens were 
immediately placed in an automated tissue processor (Peloris™, Leica, Valkenswaard, The 
Netherlands), which started with a 30 minutes formaldehyde fixation step under vacuum (see 
Supporting information for complete protocol).  
In the RUMC, CNBs were placed in Unifix (3.7 – 4% formaldehyde solution containing zinc 
sulfate, acetate buffered at pH 5,6 – 5,8; Klinipath BV, Duiven, The Netherlands) and sent to 
the pathology laboratory to be registered (estimated prior fixation time 30 minutes). If this 
5 
 
was less than 30 minutes, an extra fixation step of 30 minutes with formaldehyde was 
included. After registration, biopsy specimens were placed in a ‘rapid microwave 
histoprocessor’ (Pathos Delta, Milestone Srl, Sorisole, Italy), which included a 20 minutes 
formaldehyde fixation step (15 minutes up to 50°C and 5 minutes at a constant temperature of 
50°C) (see Supporting information for complete protocol). 
Hereafter, in both centers tissue samples were routinely embedded in paraffin. Assuming a 
preprocessing formaldehyde exposure window (including transportation to the pathology 
laboratory and administration) of 15 minutes in the UMCU and 30-60 minutes in the RUMC, 
total formaldehyde fixation time before and during processing thereby varied between 
biopsies from 45 minutes to 90 minutes. Excision specimens were fixed overnight in 
compliance with the current ASCO/CAP guideline recommendations (≥ 6 hours) [6]. Cold 
ischemia time in all included surgical specimens was less than two hours. 
 
Immunohistochemistry 
From the paraffin blocks of the tumors excised in the UMCU, one tissue microarray (TMA) 
was constructed by transferring tissue cylinders of 0.6 mm (3 cylinders per tumor) from the 
tumor area, determined by a pathologist based on haematoxylin/eosin stained slides, using a 
tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Paraffin blocks of all biopsies 
and the TMA were cut into sections of 4 μm and mounted (Table 1). In the UMCU, slides 
were baked at 37°C and manually incubated with mouse monoclonal antibodies against Ki67 
(MIB-1, dilution 1:200) from DAKO (Glostrup, Denmark) at room temperature for 60 
minutes (See Supporting information for complete staining protocol).  
In the RUMC, resection specimens were cut into whole sections of 4 μm thick and mounted. 
Slides were baked at 56°C and then immunohistochemically stained by means of the 
Immunologic Autostainer 480 (Duiven, The Netherlands) using mouse monoclonal antibodies 
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against Ki67 (MIB-1, dilution 1:100) (See Supporting information for complete staining 
protocol). Appropriate controls were used throughout.  
 
Scoring 
Ki67 percentage score was defined as the mean percentage of positively stained tumor nuclei 
(at any intensity) across all tumor cells of one slide of the same tumor at 100x magnification 
and subsequently at 40x magnification [4, 12]. In each centre, percentage of positive nuclei 
was estimated by consensus scoring of two blinded observers including an experienced breast 
pathologist (UMCU: P.v.D. and S.K.; RUMC: P.B. and A.H.). Scoring was performed 
according to the following categories: 0%, 1%, 2%, 5%, 10%, 20%, 35%, 50%, 65%, 75%, 
90% and 100%. A cut-off value of 15% for positive marker status was used according to 
current national and international recommendations [2, 3, 13, 14].  
 
Statistical analysis 
Overall agreement between the CNBs and resection specimens was calculated for Ki67 
positive and negative values. Kappa statistics were calculated to estimate the level of 
agreement beyond chance. Values of κ > 0.6, between 0.4 and 0.6, between 0.2 and 0.4, and < 
0.2 indicated good, moderate, fair and poor agreement, respectively [15]. Correlation between 
Ki67 values in CNB and resection specimens was calculated by means of Spearman’s 
correlation coefficient, using quartiles (<10%, 10-14%, 15-24%, >25%). To assess the 
accuracy of immunohistochemical tests on briefly fixed specimens in predicting either low or 
high proliferative fraction, we calculated positive and negative predictive values. In addition, 
mitotic activity scores and tumor grade distribution among resections of both cohorts were 
compared using Mann-Whitney tests. This was done to detect for differences between the two 
7 
 
cohorts. All statistics were performed using IBM SPSS Statistics for Windows (version 20.0, 
IBM Corp., Armonk, NY, USA).  
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Results 
UMCU results 
Between November 2011 and December 2012, 113 invasive breast cancers were diagnosed in 
the same-day CNB programme of the UMCU. A total of 72/113 (63.7%) cases were eligible 
for analyses. Reasons for exclusion were the administration of neo-adjuvant therapy prior to 
surgery (n = 24), multifocal disease (n = 13) and the absence of remaining diagnostic material 
(n = 4).  
Mean age of the patients was 60.6 years (ranging from 34 to 89 years). Mean time between 
CNB and surgery was 27.6 days (ranging from 7 to 51 days). A total of 43/72 (59.7%) had 
invasive ductal carcinoma, 19/72 (26.4%) invasive lobular carcinoma, 9/72 (12.5%) invasive 
ductulolobular carcinoma and 1/72 (1.4%) tubular carcinoma. In 6 patients, due to size, the 
CNB was divided over two cassettes allowing for analysis of both samples of the same CNB. 
Scores of the different slides of the same CNB were considered independent cases and were 
matched with the scores of the single corresponding resection specimens. Hence, 78 CNBs 
and 72 corresponding surgical specimens were immunohistochemically stained for Ki67.  
At immunohistochemical analysis, no deleterious effects due to processing were observed on 
the morphological preservation of the CNBs and staining intensity overall appeared no 
differently between CNBs and resection specimens. Five pairs were excluded that had no 
remaining tumor cells in the CNB or resection blocks. Thus, complete data of 68 patients (73 
CNBs and 68 resections) were apt for further analysis. Ki67 expression was high in 7/68 
(10.3%) resections and in 17/73 (23.3%) CNBs. Mean percentage of Ki67 positive tumor cells 
was 12% in the CNB group and 6% in the resection group. Overall agreement between CNB 
and resection was 64/73 (87.7%) for Ki67 expression (κ = 0.58; 95% CI = 0.32 – 0.84) (Table 
2). There was a high correlation between Ki67 values in CNBs and corresponding resections 
(rs=0.72; P < 0.01). The positive and negative predictive values for CNB Ki67 expression 
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were 47.1% (95% CI = 0.24 – 0.71) and 100.0% (95% CI = 0.92 – 1.00), respectively. 
Moderate correlation was observed between Ki67 values and mitotic activity index (rs=0.53; 
P < 0.01) and between Ki67 values and tumor grade (rs=0.57; P < 0.01) in resections (Figure 
1).  
 
RUMC results 
Between September 2012 and July 2013, 69 consecutive patients with 70 invasive breast 
cancers underwent CNB at the same-day diagnosis breast clinic of the RUMC. A total of 69 
(98.6%) cancers were eligible for analyses. One case (1.4%) was excluded because no 
remaining tumor was present in the paraffin block of the CNB. Mean age of the included 
patients was 61.3 years (ranging from 35 to 87 years). A total of 57/69 (82.6%) invasive 
cancers were invasive ductal carcinoma, 7/69 (10.1%) invasive lobular carcinoma, 2/69 
(2.9%) tubular carcinoma, 2/69 (2.9%) mucinous carcinoma, 1/69 (1.4%) micropapillary 
invasive carcinoma and 1/69 (1.4%) apocrine carcinoma. Sixty-nine CNBs and their 
corresponding resections were stained for Ki67. 
At immunohistochemical analysis, morphology was considered unremarkable in the CNBs 
and no overall differences in staining intensity were observed between CNBs and resection 
specimens. Ki67 expression was high in 50/69 (72.5%) resections and in 47/69 (68.1%) 
CNBs. Mean percentage of Ki67 positive tumor cells was 26% in the CNB group and 25% in 
the resection group. Overall agreement between CNB and resection was 58/69 (84.1%) for 
Ki67 expression (κ = 0.62; 95% CI = 0.41 – 0.83) (Table 2). There was a high correlation 
between Ki67 values in CNBs and corresponding resections (rs=0.76; P < 0.01). The positive 
and negative predictive values for biopsy Ki67 expression were 91.5% (95% CI = 0.79 – 
0.97) and 68.2% (95% CI = 0.45 – 0.85), respectively. Moderate correlation was observed 
between Ki67 values and mitotic activity index (rs=0.69; P < 0.01) and between Ki67 values 
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and tumor grade (rs=0.61; P < 0.01) in resections (Figure 2). In the RUMC cohort, Ki67 
values in resections were significantly higher than those in resections of the UMCU (P < 
0.01) (Table 3). Resections analysed in the RUMC were of significantly higher tumor grade 
than those analysed in the UMCU (P < 0.01). Mitotic activity scores were significantly higher 
in resections of the RUMC (median 11; IQR 4.00-21.00) compared with those in resections of 
the UMCU (median 5; IQR 2.25-14.00). 
 
Combined analysis of Ki67 comparability 
Overall agreement between pooled CNBs and resections was 122/142 (85.9%) for Ki67 
expression (κ = 0.71; 95% CI = 0.60 – 0.83) (Table 2). Positive and negative predictive values 
were 79.7% (95% CI = 0.67 – 0.88) and 91.0% (95% CI = 0.82 – 0.96), respectively. 
Correlation between Ki67 values in briefly fixed CNBs and conventionally fixed resections 
was high (rs = 0.82; P < 0.01), when using quartiles to categorize data (<10%, 10-14%, 15-
24%, >25%). Table 4 shows the degree of variation between discordant cases as well as the 
predominant histological subtypes. 
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Discussion 
In this double-centre study, agreement between briefly fixed CNBs and conventionally fixed 
resections was good with an observed κ value of 0.71 (95% CI = 0.60 – 0.83) and a Spearman 
correlation coefficient of 0.82 (P < 0.01). When comparing the present findings with previous 
research on agreement levels between conventionally fixed CNBs and resections, at least a 
similar level of concordance was seen. Romero et al. found an overall agreement of 76% for a 
set of 50 paired samples. The authors noted that 20% of CNBs converted from positive to 
negative in the surgical specimens as opposed to a 4% conversion from negative to positive (P 
= 0.039) [16]. A concordance rate of 73% with a κ value of 0.48 was reported by Greer et al. 
[17]. Chen et al. found a concordance rate of 79.5% (κ = 0.55) for CNBs and surgical samples 
(n = 298) [18]. Therefore, our findings indicate that brief fixation of breast cancer biopsies 
does not seem to hamper Ki67 assessment.  
Regarding Ki67 scoring inconsistencies in this study as well as in general, a few other factors 
may have accounted for the observed differences. A first factor that may have contributed to 
Ki67 scoring inconsistency is observer variation. Vörös et al. showed that Ki67 values were 
significantly influenced by the observer even if standardised criteria were used during the 
scoring process. Not only the inter-observer, but also the intra-observer agreement was found 
to be poor to moderate. Intermediate categories were generally less reproducible than low and 
high value categories [19]. High agreement levels reported for estrogen receptor expression 
between conventionally fixed CNBs and resections [20] suggest that estimating percentages 
of generally homogenously distributed positively stained nuclei may in itself be well 
reproducible, and that the much more heterogeneous distribution of Ki67 compared to other 
nuclear biomarkers inherently hampers reproducibility. In the present study, observer 
variation was minimal since all paired specimens (CNB and resection) were scored by two 
observers: in the UMCU cohort by consensus, and in the RUMC cohort by two observers with 
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excellent inter-observer agreement (weighted κ = 0.88; (95% CI = 0.84 – 0.93%)). In all 
discrepant cases between the two observers in the RUMC consensus was reached after 
evaluation of the Ki67 stained slides together with a biheaded microscope.  
Agreement between CNBs and resection specimens was slightly better in the RUMC cohort, 
in which two factors may have played a role. First, in the UMCU cohort, CNBs were 
compared with three 0.6 mm TMA cores of the resection of the same tumor. It is conceivable 
that a certain sampling error was generated because of this method, explaining perhaps the 
generally lower Ki67 values in the resection specimens in this cohort. There are no published 
systematic comparisons of the assessment of Ki67 on TMAs versus whole sections, but the 
International Ki67 in Breast Cancer Working Group speaks of anecdotal evidence that scores 
are generally lower on TMAs [4]. This may be viewed as a methodological disadvantage, as 
the TMA cores add up to a smaller tissue surface than the amount of material that an average 
CNB slide contains, potentially leading to an underestimation of Ki67 fraction. However, one 
may argue that the alternative (use of whole sections from the resections) could have had the 
opposite effect. Second, overall Ki67 values in resections were rather low in the UMCU 
cohort (which is a screening population with also lower grade and mitotic activity) where 
reproducibility is more difficult to achieve, while in the RUMC the Ki67 values (and grade 
and mitotic index) were higher with inherently higher reproducibility. The difference in 
agreement was however small (κ = 0.58 versus κ = 0.62, rs = 0.72 versus rs = 0.76), indicating 
that other methodological variations (slight differences in tissue processing and staining 
protocols) must be minimal. Preferably, we would have performed a parallel comparison 
between Ki67 percentage scores in conventionally fixed CNBs and those scores in the 
corresponding conventionally fixed resection specimens. In doing so, we could have provided 
a match-to-match baseline for assessing the efficacy of estimating Ki67 status in briefly fixed 
CNBs. However, as the CNBs were taken in the context of clinical care performing extra 
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CNBs that were to be fixed conventionally for research purposes would have put an extra  
burden on patients. Instead, we compared our findings with the agreement levels between 
conventionally fixed CNBs and conventionally fixed resections specimens that have been 
reported in the literature. 
Persisting inconsistencies in Ki67 analysis for conventionally fixed CNBs and resections and 
observer variation within the same sample, imply that implementation of Ki67 analysis in 
routine practice is still fallible. Augmenting our understanding of the biological behaviour of 
Ki67 as an immunohistochemical biomarker will most likely contribute to future 
standardization. Hereto, it appears necessary to differentiate between preanalytical factors that 
may be modified without adversely affecting Ki67 assessment and which may not. 
In conclusion, overall agreement for Ki67 expression was good between briefly fixed CNBs 
and conventionally fixed resection specimens, within the range of previous studies comparing 
conventionally fixed CNBs and resections. Therefore, it is unlikely that brief fixation as 
preanalytical variable accounts for observed differences in this study. Rather, tumor 
heterogeneity, sampling error and lower reproducibility of scoring in the low and intermediate 
categories appear to be responsible for scoring inconsistencies. Therefore, we conclude that 
brief fixation does not seem to hamper reliability of Ki67 analysis in breast cancer CNB.  
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Table 1. Ki67 analysis methodology for comparing briefly fixed CNB and conventionally 
fixed resection specimens.   
 
  
Centre UMCU RUMC 
Patients (n) 72 69 
CNBs (n) 78 70 
Resections (n) 72 70 
Antibody Mouse MoAb, clone MIB-1 Mouse MoAb, clone MIB-1 
Proportion CNB Whole sections Whole sections 
Proportion  
resection 
Tissue  
microarray Whole sections 
Staining protocol Manually Autostainer 
Consensus scoring by Observers 1 and 2 Observers 3 and 4 
   
Abbreviations: n, number; CNB, core-needle biopsy; MoAb, monoclonal antibody 
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Table 2. Comparison of Ki67 expression analysis between briefly fixed CNB and 
conventionally fixed resection specimens in two breast cancer cohorts. 
 
 
 
Table 3. Comparison of tumor grade distribution, mitotic activity and Ki67 values of 
resections between the two cohorts.  
Centre UMCU RUMC Combined 
% Positive in  CNB (n) 23.3 (17/73) 68.1 (47/69)  45.1 (64/142) 
Mean % CNBs 12 26 21 
% Positive in resection (n) 10.3 (7/68) 72.5 (50/69)  41.6 (57/137) 
Mean %  resections 6 25 15 
Overall agreement (%) 87.7 (64/73) 84.1 (58/69)  85.9 (122/142) 
Kappa (95% CI) 0.58 (0.32 – 0.84) 0.62 (0.41 – 0.83) 0.71 (0.60 – 0.83) 
% PPV (95% CI) 47.1  (0.24 – 0.71) 91.5 (0.79 – 0.97) 79.7 (0.67 – 0.88) 
% NPV (95% CI) 100.0  (0.92 – 1.00) 68.2  (0.45 – 0.85) 91.0 (0.82 – 0.96) 
Spearman’s ρ CNBs and 
resections 0.72 (P < 0.01) 0.76 (P < 0.01) 0.82 (P < 0.01) 
    
Abbreviations: CNB, core-needle biopsy; PPV, positive predictive value; NPV, negative predictive value; 
95% CI, 95% confidence interval; Spearman’s  ρ, correlation coefficient; P, P value for significance. 
Centre  UMCU (n = 68) RUMC (n = 69) P-value 
Grade I 22 (32.4%) 13 (18.8%)  
 II 30 (44.1%) 25 (36.2%) <0.01 
 III 16 (23.5%) 31 (44.9%)  
Median Ki67 expression (%)  3.5 (IQR 2.00 -8.75) 20 (IQR 10.00-35.00) <0.01 
Median mitotic activity (n/2mm2)  5 (IQR 2.25-14.00) 11 (IQR 4.00-21.00) <0.01 
  
Abbreviations: IQR, interquartile range; n, number; P, P value for significance. 
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 Table 4. Ki67 discordant cases (n = 20). 
Degree of variation n cases CNB>R IDC ILC Other 
≤10% 13/20 (65,0%) 8/13 (61,5%) 9/13 (69,2%) 3/13 (23.1%) 1/13 (7,7%) 
>10 – 30% 6/20 (30,0%) 4/6 (66,7%) 5/6 (83,3%) 1/6 (16.7%) - 
>30% 1/20 (5,0%) 1/1 (100%) 1/1 (100%) - - 
Total 20 (100%) 13/20 (65,0%) 15/20 (75,0%) 4/20 (20,0%) 1/20 (5,0%) 
 
Abbreviations: n, number; CNB>R, positivity score higher in core-needle biopsy than in resection 
specimen; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Other, other histological 
subtype. 
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Table 4.  
  
 
 
 
 
 
  
 Ki67 expression CNB Ki67 expression resection Degree of variation Histological subtype 
 35 5 30 IDC 
 20 10 10 IDC 
 20 5 15 IDC 
 35 10 25 IDC 
 90 10 80 IDC 
 20 10 10 IDC 
 20 10 10 IDC 
 20 10 10 IDC 
 20 10 10 ILC 
 2 20 18 IDC 
 10 20 10 ILC 
 20 5 15 ILC 
 10 20 10 IDC 
 10 20 10 IDC 
 10 20 10 IDC 
 20 10 10 IDC 
 20 10 10 IDC 
 20 10 10 Mucinous  
 10 35 25 IDC 
 10 20 10 ILC 
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Figure Legends 
Figure 1: Two Ki67 discordant cases of the UMCU with high (≥15%) Ki67 expression values 
in briefly fixed biopsies (top and bottom left) but low expression values in corresponding 
resection specimens (top and bottom right); (all parts ×200). 
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Figure 2: One Ki67 discordant and one Ki67 concordant case of the RUMC. Low (<15%) 
Ki67 expression values in a briefly fixed biopsy (top left) but high expression values in the 
corresponding resection specimen (top right); low Ki67 expression values in a briefly fixed 
biopsy (bottom left) and low expression values in the corresponding resection specimen 
(bottom right); (all parts ×200). 
 
